ARRY News 3.79 Array Biopharma Inc (ARRY)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Array Biopharma Inc (ARRY) 3.79 $ARRY

Investors look to Lighten Up on Shares of Array Biopharma, Shares Down 7.2% (ARRY)
Comtex SmarTrend(R) - Tue Apr 15, 12:48PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 7.2% to $3.47 on 1.0x average daily volume. Array Biopharma has traded 1.6 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-7.2% to the Dow's -0.2%) and underperformed the S&P 500 (-7.2% to the S&P's -0.2%) during today's trading.

Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Hot Stock: Array Biopharma, Shares Drop 5.7% (ARRY)
Comtex SmarTrend(R) - Fri Apr 04, 12:45PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.7% to $4.14 on 1.2x average daily volume. Thus far today, Array Biopharma has traded 1.8 million shares, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.5%) and underperformed the S&P 500 (-5.7% to the S&P's -0.8%) during today's trading.

Biotech Stocks Analysis -- Research on Array BioPharma, ACADIA Pharma, Pharmacyclics, and Isis Pharma
PR Newswire - Fri Mar 28, 5:40AM CDT
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:

Stock to Watch: Array Biopharma Down 5.2% (ARRY)
Comtex SmarTrend(R) - Thu Mar 27, 12:46PM CDT
Array Biopharma (NASDAQ:ARRY) is one of today's worst performing low-priced stocks, down 5.2% to $4.54 on 1.3x average daily volume. Array Biopharma has traded 1.7 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.1%) and underperformed the S&P 500 (-5.2% to the S&P's -0.3%) during today's trading.

Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.

Oi S.A. - MATERIAL FACT: Consolidation of the Activities and Businesses of Oi and Portugal Telecom
PR Newswire - Thu Feb 20, 3:03AM CST
Oi S.A. ("Oi" or the "Company", Bovespa: OIBR3, OIBR4; NYSE: OIBR and OIBR.C) and Telemar Participacoes S.A. ("CorpCo" , in accordance with article 157, paragraph 4 of Law No. 6,404/76 (the "Brazilian Corporations Law" and CVM Instruction No. 358/02, notifies their shareholders and the market in general of the previously informed transaction of the combination, in one entity, of the activities and business operations of Oi in Brazil and Portugal Telecom, SGPS, S.A. ("Portugal Telecom" in Portugal and Africa, consolidating the industrial alliance between Oi and Portugal Telecom, initiated in 2010 and developed since that time, and combining the shareholder bases of Oi, Portugal Telecom and CorpCo (the "Transaction" .

Array BioPharma To Present At The RBC Capital Markets Global Healthcare And Cowen Annual Healthcare Conferences
PR Newswire - Tue Feb 18, 11:45AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the RBC Capital Markets Global Healthcare and Cowen Annual Healthcare Conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website.

Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 06, 3:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Why Array Biopharma Inc. Shares (Briefly) Popped
Alex Planes, The Motley Fool - Motley Fool - Tue Feb 04, 11:42AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Array Biopharma   opened 10% higher this...

Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2014
PR Newswire - Tue Feb 04, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2014.

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Mon Feb 03, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.

Brandywine Realty Trust Announces Tax Characteristics of Its 2013 Distributions
PR Newswire - Wed Jan 29, 3:30PM CST
Brandywine Realty Trust (NYSE: BDN) announced today the tax characteristics of its 2013 distributions. The tax reporting will be done on Form 1099-DIV and shareholders are encouraged to consult with their personal tax advisors as to the specific tax treatment of dividends. The characteristics of the Company's distributions are as follows:

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2014 on February 4, 2014
PR Newswire - Wed Jan 29, 10:00AM CST
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy" List for Tuesday

Annual J.P. Morgan Healthcare Conference Presentations, Results of Self-Tender Offer, and Executive Appointment - Research Report on ICU Medical, Integra, Taro, AMAG, and Array BioPharma
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference
PR Newswire - Fri Jan 03, 12:30PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
PR Newswire - Fri Dec 20, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Brave Healer Productions Unveils Transformational Book Series

Updated Category News Views 253

Brave Healer Productions Unveils Transformational Book Series Brave Healer Productions has made an exciting announcement with the introduction of Shaman Heart: We Are the Ones We've Been Waiting For, the third volume in the acclaimed Shaman Heart series. This significant release highlights the wisdom of 26 courageous healers, teachers, and spiritual mentors who embarked...

Continue Reading
Empowering Fans: Miss Universe Adopts Blockchain Voting App

Updated Category News Views 314

Revolutionizing Fan Engagement with Blockchain Technology In a historical move that blends tradition with technology, the Miss Universe Organization (MUO) has partnered with Zetrix to unveil the Miss Universe Global Blockchain Voting App. This strategic alliance aims to empower fans worldwide by facilitating secure and trustworthy voting experiences, marking a significant...

Continue Reading
Occidental Bets Big on Argentine Sunflower Boom

Updated Category News Views 64

The Sunflower Seed Gamble When a company like Occidental Resources plunks down $200 million for sunflower seeds, you sit up and take notice. We're talking 300,000 metric tons of those little yellow gems sourced from Argentina, which according to the Rosario Board of Trade, is rolling in a whopping 6.6 million metric tons of sunflower product this year. Doesn't sound like...

Continue Reading
Martini Market’s $MRT Presale: Last Chance to Seize the Opportunity

Updated Category News Views 207

The Exciting Conclusion of the Martini Market Presale As the highly anticipated $MRT token presale approaches its final days, the excitement is palpable in the decentralized finance (DeFi) community. With just a few days left, Martini Market has established itself as a frontrunner in the realm of decentralized prediction markets on the XRP Ledger. What Makes Martini...

Continue Reading
Samsara Intelligence: Transforming Operations with AI Power

Updated Category News Views 345

Revolutionizing Operations with Samsara Intelligence Samsara Inc. (NYSE: IOT), a trailblazer in the Connected Operations Cloud space, has just launched Samsara Intelligence. This sophisticated suite of AI offerings is crafted to assist businesses in making informed decisions, thereby streamlining operations while ensuring safety. Harnessing an extensive database that...

Continue Reading